{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:55:20Z","timestamp":1770749720037,"version":"3.50.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>All colorectal cancer (CRC) survivors have an increased risk of developing second primary malignancies (SPMs). The association between diabetes mellitus (DM) and the risk of cancer is well known. However, the role of DM and its therapy in the development of SPMs in CRC patients is not well described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single-institutional retrospective analysis we identified 1,174 colorectal carcinoma patients, median follow-up 10.1 years, (median age 63 years, 724 men). All  patients over 18 years with histologically confirmed CRC who were admitted in the period 1.1. 2003- 31.12.2013 and followed-up till 31.12. 2018 at the Masaryk Memorial Cancer Institute (MMCI) were screened for eligibility. The exclusion criteria were CRC diagnosed at autopsy, lost to follow-up and high risk of development of SPMs due to hereditary cancer syndrome. Tumours are considered multiple primary malignancies if arising in different sites and\/or are of a different histology or\u00a0morphology\u00a0group. Comparisons of the basic characteristics between the patients with SPM and the patients without SPM were performed as well as comparison of the occurrence of SPMs by the site of diagnosis between the DM and non-DM cohorts and survival analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A SPM was diagnosed in 234 (20%) patients, DM in 183 (15%) patients. DM was diagnosed in 22.6% of those with SPM vs. in 13.8% of those without SPM (p=0.001). The most common types of SPMs in DM patients were other CRC, kidney, lung, bladder and nonmelanoma skin cancer, but only carcinoma of the liver and bile duct tracts was significantly more common than in the group without DM. Although breast cancer was the second most common in the group with DM, its incidence was lower than in the group without DM, as well as prostate cancer. A significantly higher incidence of SPMs was found in older CRC patients (\u2265 65 years) and in those with lower stage colon cancer and DM. No significant difference in DM treatment between those with and without a SPM was observed including analysis of type of insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CRC patients with diabetes mellitus, especially those with older age, and early stages of colon cancer, should be screened for second primary malignancies more often than the standard population. Patients without DM have longer survival. According to the occurrence of the most common second malignancies, a clinical examination, blood count, and ultrasound of the abdomen is appropriate, together with standard breast and colorectal cancer screening, and lung cancer screening under certain\u00a0conditions, and should be recommended in CRC survivors especially in patients with intercurrent DM, however the necessary frequency of screening remains unclear.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2020.573394","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T08:40:15Z","timestamp":1611909615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Jana","family":"Halamkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Pehalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Gonec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Kozakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Bohovicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Slaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Demlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14735\/amko201530","article-title":"Estimating Cancer Incidence, Prevalence, and the Number of Cancer Patients Treated With Antitumor Therapy in 2015 and 2020 - Analysis of the Czech National Cancer Registry","volume":"28","author":"Dusek","year":"2015","journal-title":"Klin Onkol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30164","article-title":"Risk of Second Primary Malignancies Among Cancer Survivors in the United States, 1992 Through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/1477-3163.78114","article-title":"Risk of Second Primary Colorectal Cancer Among Colorectal Cancer Cases: A Population-Based Analysis","volume":"10","author":"Raj","year":"2011","journal-title":"J Carcinog"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and Cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0508-7","article-title":"Insulin, Insulin Receptors, and Cancer","volume":"39","author":"Vigneri","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2002","article-title":"Insulin Therapy and Cancer","author":"Home","year":"2013","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00030.2014","article-title":"Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality","volume":"95","author":"Gallagher","year":"2015","journal-title":"Physiol Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2013.01.014","article-title":"Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-Analysis Using Primary Data of Published Studies","volume":"62","author":"Thakkar","year":"2013","journal-title":"Metabolism"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.diabet.2012.08.011","article-title":"Insulin Use and Cancer Risk in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Observational Studies","volume":"38","author":"Colmers","year":"2012","journal-title":"Diabetes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.5.0442","article-title":"Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs","volume":"22","author":"Vajo","year":"2001","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1468","article-title":"The Association of Basal Insulin Glargine and\/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia","volume":"37","author":"Bordeleau","year":"2014","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1452-2","article-title":"Similar Risk of Malignancy With Insulin Glargine and Neutral Protamine Hagedorn (NPH) Insulin in Patients With Type 2 Diabetes: Findings From a 5 Year Randomised, Open-Label Study","volume":"52","author":"Rosenstock","year":"2009","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2337\/dc12-0506","article-title":"Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French Nationwide Cohort Study Based on National Administrative Databases","volume":"36","author":"Fagot","year":"2013","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2016.1155736","article-title":"Insulin Glargine Use and Breast Cancer Risk: Associations With Cumulative Exposure","volume":"55","author":"Peeters","year":"2016","journal-title":"Acta Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2012.03.004","article-title":"Critical Appraisal of the Recent Data Published on the Link Between Insulin and Cancer","volume":"5","author":"Ghosal","year":"2011","journal-title":"Diabetes Metab Syndr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1530-5","article-title":"Combined Randomised Controlled Trial Experience of Malignancies in Studies Using Insulin Glargine","volume":"52","author":"Home","year":"2009","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1816","article-title":"Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies","volume":"39","author":"Wu","year":"2016","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.770469","article-title":"Glargine Safety, Diabetes and Cancer","volume":"12","author":"Rendell","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2018.02.010","article-title":"Long-acting Insulin Analogs and Cancer","volume":"28","author":"Sciacca","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110386","article-title":"Cellular and Molecular Mechanisms of Metformin: An Overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1805","article-title":"Metformin: A Therapeutic Opportunity in Breast Cancer","volume":"16","author":"Gonzalez-Angulo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for Chemoprevention of Metachronous Colorectal Adenoma or Polyps in Post-Polypectomy Patients Without Diabetes: A Multicentre Double-Blind, Placebo-Controlled, Randomised Phase 3 Trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2015.13.2.145","article-title":"Inhibitory Effect of Metformin Therapy on the Incidence of Colorectal Advanced Adenomas in Patients With Diabetes","volume":"13","author":"Kim","year":"2015","journal-title":"Intest Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2018.01.007","article-title":"Metformin: Prevention of Genomic Instability and Cancer: A Review","volume":"827","author":"Najafi","year":"2018","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12820","article-title":"Metformin Exposure and Survival in Head and Neck Cancer: A Large Population-Based Cohort Study","volume":"44","author":"Alcusky","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17066","article-title":"Metformin and Lung Cancer Risk in Patients With Type 2 Diabetes Mellitus","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2015.09.027","article-title":"Use of Metformin and Risk of Kidney Cancer in Patients With Type 2 Diabetes","volume":"52","author":"Tseng","year":"2016","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13762","article-title":"Metformin Therapy and Risk of Colorectal Adenomas and Colorectal Cancer in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an Adjuvant Treatment for Cancer: A Systematic Review and Meta-Analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5541","article-title":"Metformin Prevents Cancer Metastasis by Inhibiting M2-like Polarization of Tumor Associated Macrophages","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple Primary Tumours: Challenges and Approaches, a Review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"B33","volume-title":"Multiple primary neoplasms","year":""},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200508000-00002","article-title":"International Rules for Multiple Primary Cancers (ICD-0 Third Edition)","volume":"14","year":"2005","journal-title":"Eur J Cancer Prev"},{"key":"B35","unstructured":"National Health Information System (NHIS), Czech National Cancer Registry (CNCR)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0266","article-title":"Second Primary Malignancies in Patients With Colorectal Cancer: A Population-Based Analysis","volume":"25","author":"Jia","year":"2020","journal-title":"Oncologist"},{"key":"B37","article-title":"Second Primary Malignancies Associated With Primary Female Breast Cancer: A Review of the Danbury Hospital Experience","volume":"56","author":"La Francis","year":"1992","journal-title":"Conn Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.4.1152","article-title":"Second Primary Tumors Involving Non-Small Cell Lung Cancer: Prevalence and Its Influence on Survival","volume":"127","author":"Duchateau","year":"2005","journal-title":"Chest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1079","DOI":"10.1097\/MD.0000000000001079","article-title":"Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity With Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.04.012","article-title":"Relationships of Obesity and Diabetes Mellitus to Other Primary Cancers in Surgically Treated Gastric Cancer Patients","volume":"12","author":"Takeuchi","year":"2014","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07326-7","article-title":"Sidedness of Colorectal Cancer Impacts Risk of Second Primary Gastrointestinal Malignancy","volume":"26","author":"Broman","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1035-4","article-title":"Relationship between diabetes and risk of second primary contralateral breast cancer","volume":"125","author":"Li","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S187614","article-title":"Second primary malignancy in patients with cholangiocarcinoma: a population-based study","volume":"11","author":"Zhuang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14472","article-title":"2017 Update on the Relationship Between Diabetes and Colorectal Cancer: Epidemiology, Potential Molecular Mechanisms and Therapeutic Implications","volume":"8","author":"Gonz\u00e1lez","year":"2017","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0699","article-title":"Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients","volume":"34","author":"Morden","year":"2011","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0426","article-title":"Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival","volume":"20","author":"Kwon","year":"2015","journal-title":"Oncologist"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15692","article-title":"Metformin Is Associated With Survival Benefit in Pancreatic Cancer Patients With Diabetes: A Systematic Review and Meta-Analysis","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-0424","article-title":"A Cohort Study of Metformin and Colorectal Cancer Risk Among Patients With Diabetes Mellitus","volume":"27","author":"Bradley","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-364","article-title":"Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-Based Historical Cohort","volume":"12","author":"Dankner","year":"2012","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00125-011-2312-4","article-title":"Risk of cancer in patients on insulin glargine and other insulin analogs in comparison with those on human insulin: results from a large population-based follow-up study","volume":"55","author":"Ruiter","year":"2012","journal-title":"Diabetologia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113136660067","article-title":"Use of Insulin and Insulin Analogs and Risk of Cancer - Systematic Review and Meta-Analysis of Observational Studies","volume":"8","author":"Karlstad","year":"2013","journal-title":"Curr Drug Saf"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3109\/13813451003631439","article-title":"Treatment With Insulin Glargine (Lantus) Increases the Proliferative Potency of the Serum of Patients With type-1 Diabetes: A Pilot Study on MCF-7 Breast Cancer Cells","volume":"116","author":"Mayer","year":"2010","journal-title":"Arch Physiol Biochem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4312-5","article-title":"Cancer Risk Among Insulin Users: Comparing Analogues With Human Insulin in the CARING Five-Country Cohort Study","volume":"60","author":"But","year":"2017","journal-title":"Diabetologia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.8444","article-title":"Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies","volume":"32","author":"Gibson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000447","article-title":"Second Primary Cancers and Survival in Patients With Gastric Cancer: Association With Prediagnosis Lifestyles","volume":"28","author":"Morais","year":"2019","journal-title":"Eur J Cancer Prev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.8681","article-title":"Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction","volume":"30","author":"Wood","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.573394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T08:40:18Z","timestamp":1611909618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.573394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":56,"alternative-id":["10.3389\/fonc.2020.573394"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.573394","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"article-number":"573394"}}